



LKT Laboratories, Inc.

## (-)-Huperzine A

Phone: 888-558-5227  
651-644-8424  
Fax: 888-558-7329  
Email: [getinfo@lktlabs.com](mailto:getinfo@lktlabs.com)  
Web: [lktlabs.com](http://lktlabs.com)

### Product Information

**Product ID** H8162

**CAS No.** 102518-79-6

**Chemical Name** 1-amino-13-ethylidene-11-methyl-6-aza-tricyclo- [7.3.1.0.2,7]trideca-2(7),3,10-trien-5-one

**Synonym** HupA

**Formula** C<sub>15</sub>H<sub>18</sub>N<sub>2</sub>O

**Formula Wt.** 242.32

**Melting Point** 214-215°C


**Purity** ≥97%

**Solubility** Soluble in DMSO, ethanol, methanol, and aqueous acids.

**Store Temp** 4°C

**Ship Temp** Ambient

**Description** Huperzine A (HupA) is a sesquiterpene alkaloid derived from the fir-like moss *Huperzia serrata*; it exhibits anticonvulsant/antiepileptic, neuromodulatory, cognition enhancing, neuroprotective, and antinociceptive activities. HupA acts as a reversible, selective acetylcholinesterase (AChE) inhibitor and is being explored in clinical trials as a potential treatment for Alzheimer's Disease. Several studies have shown HupA to improve cognition, memory, mood, and/or daily activities at a range of doses. Additionally, HupA's comparatively long-lasting binding of AChE is protective against organophosphate-induced seizure and status epilepticus. In cellular and animal models, this compound exhibits non-competitive, reversible antagonist activity at NMDA receptors. HupA is also under examination as a potential non-dependence-inducing antinociceptive, as it blocks chemical, thermal, and mechanical pain stimulation in vivo.



**Bulk quantities available upon request**

Product ID	Size
H8162	1 mg
H8162	5 mg

**References** Yu D, Thakor DK, Han I, et al. Alleviation of chronic pain following rat spinal cord compression injury with multimodal actions of huperzine A. *Proc Natl Acad Sci U S A.* 2013 Feb 19;110(8):E746-55. PMID: 23386718.

Rafii MS, Walsh S, Little JT, et al. A phase II trial of huperzine A in mild to moderate Alzheimer disease. *Neurology.* 2011 Apr 19;76(16):1389-94. doi: PMID: 21502597.

Park P, Schachter S, Yaksh T. Intrathecal huperzine A increases thermal escape latency and decreases flinching behavior in the formalin test in rats. *Neurosci Lett.* 2010 Feb 5;470(1):6-9. PMID: 20026382.

Zhang Z, Wang X, Chen Q, et al. Clinical efficacy and safety of huperzine Alpha in treatment of mild to moderate Alzheimer disease, a placebo-controlled, double-blind, randomized trial. *Zhonghua Yi Xue Za Zhi.* 2002 Jul 25;82(14):941-4. PMID: 12181083.

Gordon RK, Nigam SV, Weitz JA, et al. The NMDA receptor ion channel: a site for binding of Huperzine A. *J Appl Toxicol.* 2001 Dec;21 Suppl 1:S47-51. PMID: 11920920.

Camps P, El Achab R, Morral J, et al. [New tacrine-huperzine A hybrids \(huprines\): highly potent tight-binding acetylcholinesterase inhibitors of interest for the treatment of Alzheimer's disease.](#) *J Med Chem.* 2000 Nov 30;43(24):4657-66. PMID: 11101357.

**Caution:** This product is intended for laboratory and research use only. It is not for human or drug use.